Abstract
PURPOSE: To report central serous chorioretinopathy associated with excessive use of compounds with sympathomimetic activity. DESIGN: Observational case series. METHODS: Four patients presented with clinical and fluorescein angiographic evidence of central serous chorioretinopathy. All patients expressed a concomitant psychogenic stress and high-dose ingestion of pseudoephedrine, oxymetazoline, or 3,4-methylenedioxymethamphetamine, all of which possess sympathomimetic properties. RESULTS: In all cases, resolution of central serous chorioretinopathy coincided with cessation of the medication. CONCLUSIONS: Patients afflicted with central serous chorioretinopathy should be notified about its possible association with sympathomimetic medications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 182-185 |
| Number of pages | 4 |
| Journal | American Journal of Ophthalmology |
| Volume | 136 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 1 2003 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Central serous chorioretinopathy associated with administration of sympathomimetic agents. / Michael, John C.; Pak, John; Pulido, Jose S; De Venecia, Guillermo.
In: American Journal of Ophthalmology, Vol. 136, No. 1, 01.07.2003, p. 182-185.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Central serous chorioretinopathy associated with administration of sympathomimetic agents
AU - Michael, John C.
AU - Pak, John
AU - Pulido, Jose S
AU - De Venecia, Guillermo
PY - 2003/7/1
Y1 - 2003/7/1
N2 - PURPOSE: To report central serous chorioretinopathy associated with excessive use of compounds with sympathomimetic activity. DESIGN: Observational case series. METHODS: Four patients presented with clinical and fluorescein angiographic evidence of central serous chorioretinopathy. All patients expressed a concomitant psychogenic stress and high-dose ingestion of pseudoephedrine, oxymetazoline, or 3,4-methylenedioxymethamphetamine, all of which possess sympathomimetic properties. RESULTS: In all cases, resolution of central serous chorioretinopathy coincided with cessation of the medication. CONCLUSIONS: Patients afflicted with central serous chorioretinopathy should be notified about its possible association with sympathomimetic medications.
AB - PURPOSE: To report central serous chorioretinopathy associated with excessive use of compounds with sympathomimetic activity. DESIGN: Observational case series. METHODS: Four patients presented with clinical and fluorescein angiographic evidence of central serous chorioretinopathy. All patients expressed a concomitant psychogenic stress and high-dose ingestion of pseudoephedrine, oxymetazoline, or 3,4-methylenedioxymethamphetamine, all of which possess sympathomimetic properties. RESULTS: In all cases, resolution of central serous chorioretinopathy coincided with cessation of the medication. CONCLUSIONS: Patients afflicted with central serous chorioretinopathy should be notified about its possible association with sympathomimetic medications.
UR - http://www.scopus.com/inward/record.url?scp=0038692189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038692189&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(03)00076-X
DO - 10.1016/S0002-9394(03)00076-X
M3 - Article
C2 - 12834690
AN - SCOPUS:0038692189
VL - 136
SP - 182
EP - 185
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 1
ER -